Patents Assigned to Inserm
  • Methods for the prevention and the treatment of extracapillary glomerulonephritis
    Patent number: 10344279
    Abstract: The present invention relates to the prevention and the treatment of extracapillary glomerulonephritis such as rapidly progressive glomerulonephritis and collapsing glomerulonephritis.
    Type: Grant
    Filed: August 9, 2017
    Date of Patent: July 9, 2019
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MĖDICALE), UNIVERSITÉ PARIS DESCARTES
    Inventors: Pierre-Louis Tharaux, Carole Henique-Greciet
  • IMMUNOMODULATION AFTER LOCOREGIONAL ANTI-TUMORAL TREAMENT
    Publication number: 20190201492
    Abstract: The present invention concerns a thermosensitive polymeric hydrogel comprising at least one thermosensitive copolymer, one aqueous solution, and a mucoadhesive excipient, wherein said thermosensitive polymeric hydrogel further comprises at least one immunostimulatory adjuvant and/or at least one cytokine and/or at least one chemokine and/or atleast one heat shockprotein. Another object of the invention is a thermosensitive polymeric hydrogel according to the invention for use in the treatment of tumors or metastasis in a subject having a cancer, preferably a metastatic cancer.
    Type: Application
    Filed: August 31, 2017
    Publication date: July 4, 2019
    Applicants: Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Universite Paris Descartes, Assistance Publique - Hopitaux de Paris, Ecole Nationale Superieure de Chimie de Paris, Universite de Versailles-St Quentin en Yvelines
    Inventors: Robert Malafosse, Nathalie Mignet, Vincent Boudy, Johanne Seguin, Kathia Lemdani, Claude Capron
  • ANTI-CD277 ANTIBODIES AND USES THEREOF
    Publication number: 20190201513
    Abstract: Described herein are anti-CD277 antibodies which: activates or inhibit the cytolytic function of V?9/V?2 T cells, and/or costimulates T cells together with CD3-TCR, and/or costimulates T cells in addition to CD28-B7 costimulation, and/or increases the activity and/or survival of monocytes and dendritic cells. The use of said antibodies in therapy is also described.
    Type: Application
    Filed: February 22, 2019
    Publication date: July 4, 2019
    Applicants: Institut National de la Santé et de la Recherche Médicale (INSERM), Universite D'Aix-Marseille, Institut Jean Paoli & Irene Calmettes, Centre National De La recherche Scientifique (CNRS), Universite De Nantes
    Inventors: Daniel OLIVE, Marc BONNEVILLE, Emmanuel SCOTET, Christelle HARLY, Yves GUILLAUME
  • Methods for predicting the progression and treating a chronic kidney disease in a patient
    Patent number: 10337008
    Abstract: The present invention relates to a method for predicting the progression of chronic kidney disease (CKD) in a patient and also to an inhibitor of NGAL gene expression or an NGAL antagonist for use in the prevention or the treatment of CKD.
    Type: Grant
    Filed: May 12, 2016
    Date of Patent: July 2, 2019
    Assignee: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Fabiola Terzi, Amandine Viau, Clément Nguyen, Martine Burtin, Khalil El Karoui
  • GELLING COMPOSITIONS FOR TREATING MALIGNANT TUMOURS AND/OR PREVENTING TUMOUR RECURRENCE
    Publication number: 20190192430
    Abstract: The present invention relates to gelling compositions, which changes from liquid state to gel state in function of temperature comprising: at least a poloxamer or mixture of poloxamers; at least a gelling agent; and at least an anticancer agent. Said compositions are advantageously used for local administration of an anticancer agent. Said compositions are useful for size-reduction of a tumour before surgical removal of said tumour, for preventing tumour recurrence after surgical removal of a tumour, and/or treating small tumours. They are therefore useful for the treatment of cancer, preferably a cancer of a wall of the digestive system or a gynaecologic cancer. The present invention also relates to a method for preparing said gelling compositions.
    Type: Application
    Filed: September 16, 2016
    Publication date: June 27, 2019
    Applicants: Centre National de la Recherche Scientifique (CNRS), Universite Paris Descartes, Assistance Publique-Hopitaux de Paris, Ecole Nationale Superieure de Chimie de Paris, Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Nathalie Mignet, Vincent Pierre-Marie Boudy, Johanne Seguin, Daniel Scherman, Yoran Beldengrun
  • Method for characterising an ultrasound wound in organic tissues
    Patent number: 10327732
    Abstract: The method of characterizing an ultrasound lesion (T) in organic tissues, the lesion being made by applying high intensity focused ultrasound delivered by a probe having its emission surface presenting a shape that is toroidal, consists in: after a period of at least two days from the end of ultrasound application, acquiring at least one characterization image (Ic) of the organic tissues; detecting the presence of a contrast border (16) in the characterization image (Ic); and from the contrast border (16), determining the extent of the ultrasound lesion.
    Type: Grant
    Filed: October 7, 2014
    Date of Patent: June 25, 2019
    Assignees: EDAP TMS FRANCE, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
    Inventors: David Melodelima, Jeremy Vincenot, Emmanuel Blanc
  • USE OF SERINE PROTEASE INHIBITORS IN THE TREATMENT OF SKIN DISEASES
    Publication number: 20190183989
    Abstract: This invention relates to therapeutic compounds which are inhibitors of serine proteases, to pharmaceutical compositions thereof and to their use in the treatment of the human or animal body. More specifically, the present invention relates to a method for the treatment, diagnosis or prognosis of skin diseases comprising the administration to a subject in need thereof of a therapeutically effective amount of a Serine protease inhibitor.
    Type: Application
    Filed: December 12, 2018
    Publication date: June 20, 2019
    Applicants: DERMADIS SA, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: David Deperthes, Christoph Kundig, Alain Hovnanian, Celine Deraison
  • Isolated peptides and fragments thereof from fibrinogen for use as drugs, particularly in skin inflammatory diseases
    Patent number: 10323078
    Abstract: A present invention relates to isolated peptides obtained from human fibrinogen for their use as drug, particularly for the prevention and/or the treatment of inflammatory skin diseases, more particularly acne. The present invention also relates to fragments of these polypeptides, nucleic acid molecules encoding them, expression vectors, host cells, a pharmaceutical composition and a combination product containing them, and their use for treating and/or preventing inflammatory skin diseases, particularly acne.
    Type: Grant
    Filed: March 21, 2016
    Date of Patent: June 18, 2019
    Assignees: Universite Paris Descartes, Assistance Publique—Hopitaux De Paris, Universite Paris—Sud, Universite Pierre et Marie Curie (Paris 6), Institut National De La Sante et De La Recherche Medicale (INSERM), Centre National De La Recherche Scientifique (CNRS), Institut Gustave-Roussy
    Inventors: Nicolas Dupin, Philippe Grange, Vincent Calvez, Joël Raingeaud
  • Hepatitis B virus pre-S1 derived synthetic polypeptides and uses thereof
    Patent number: 10323068
    Abstract: The invention relates to a group of synthetic polypeptides, derived from the pre-S1 region of HBV, that efficiently interfere with early steps of an HBV infection. The peptides of the invention can be used in diagnostics for the detection of antigens and/or antibodies.
    Type: Grant
    Filed: November 18, 2015
    Date of Patent: June 18, 2019
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Philippe Gripon, Stephan Urban
  • Imidazol- or 1,2,4-triazol-derivatives and their use
    Patent number: 10323016
    Abstract: The present invention is directed to novel compounds of formula (I), pharmaceutically acceptable salts or solvates thereof, and their use.
    Type: Grant
    Filed: June 11, 2015
    Date of Patent: June 18, 2019
    Assignees: UNIVERSITE DE LILLE 2 DROIT ET SANTE, INSTITUT PASTEUR DE LILLE, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
    Inventors: Julie Charton, Benoit Deprez, Florence Leroux, Bart Staels, Anne Muhr-Tailleux, Nathalie Hennuyer, Sophie Lestavel, Manuel Lassalle, Barbara Dubanchet
  • Methods and pharmaceutical compositions for the treatment of ischemic conditions
    Patent number: 10322162
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of ischemic conditions. In particular, the present invention relates to a method of treating an ischemic condition in a subject in need thereof comprising administering the subject with a polypeptide comprising an amino acid sequence having at least 70% of identity with the amino acid sequence ranging from the amino acid residue at position 186 to the amino acid residue at position 406 in SEQ ID NO: 1.
    Type: Grant
    Filed: January 6, 2016
    Date of Patent: June 18, 2019
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), COLLEGE DE FRANCE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE PARIS-EST CRETEIL VAL DE MARNE, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP), ECOLE NATIONALE VETERINAIRE D'ALFORT (ENVA)
    Inventors: Stéphane Germain, Alain Berdeaux, Renaud Tissier, Bijan Ghaleh-Marzban, Catherine Monnot, Ariane Galaup
  • USE OF CD31 PEPTIDES IN THE TREATMENT OF THROMBOTIC AND AUTOIMMUNE DISORDERS
    Publication number: 20190177396
    Abstract: The present invention stems from the finding that the extracellular domain of CD31 proteins present on blood leukocytes is shed and released in the circulation as a soluble form of CD31. The invention relates to peptides corresponding to fragments of CD31 that inhibit T-cell response, and to their use in the treatment of thrombotic disorders such as atherothrombosis and autoimmune disorders.
    Type: Application
    Filed: February 22, 2019
    Publication date: June 13, 2019
    Applicant: INSERM (Institute National de la Sante et de la Recherche Medicale
    Inventors: Giuseppina Caligiuri, Antonino Nicoletti
  • DEVICE FOR ILLUMINATING AN OBJECT WITH A CONTROLLED LIGHT INTENSITY AND ASSOCIATED METHOD
    Publication number: 20190175934
    Abstract: The invention concerns a device 10 for illuminating an object 12 with a controlled light intensity, the light intensity being controlled when the light intensity fulfills a plurality of conditions to be fulfilled, the plurality of conditions comprising a condition relative to the intensity at a given time and a condition relative to the dose during a period of time.
    Type: Application
    Filed: June 16, 2017
    Publication date: June 13, 2019
    Applicants: Sorbonne Université, Centre national de la recherche scientifique, Institut National de la Sante et de la Recherche Medicale (Inserm), Gensight Biologics
    Inventors: Joël CHAVAS, Guillaume CHENEGROS, Benjamin R. BENOSMAN
  • Methods for selecting binders by phage display and masked selection
    Patent number: 10316315
    Abstract: The present invention relates to methods for selecting binders by phage display and masked selection. More particularly, the present invention relates to a method for selecting a plurality of binders specific for at least one relevant target comprising screening a phage binder library of binders against the relevant target in presence of a plurality of binders obtained from a library of binders directed against at least one irrelevant target and positively selecting the binders that are specific for the at least one relevant target.
    Type: Grant
    Filed: February 8, 2017
    Date of Patent: June 11, 2019
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE D'AIX-MARSEILLE, INSTITUT JEAN PAOLI & IRENE CALMETTES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Daniel Baty, Patrick Chames
  • Use of a genetically modified infectious measles virus with enhanced pro-apoptotic properties (MV-deltaC virus) in cancer therapy
    Patent number: 10314905
    Abstract: The invention relates to a genetically modified infectious measles virus derived from a live-attenuated measles virus strain, in which the gene encoding the viral accessory C protein has been knocked out (MV-deltaC). It concerns in particular the use of said genetically modified infectious MV-deltaC in the treatment of malignant tumor or cancer conditions, and for the preparation of agents or compositions for such treatment.
    Type: Grant
    Filed: January 25, 2018
    Date of Patent: June 11, 2019
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCENTIFIQUE (CNRS), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), INSTITUT PASTEUR, UNIVERSITE DE NANTES
    Inventors: Frédéric Tangy, Marc Gregoire, Jean-François Fonteneau, Jean-Baptiste Guillerme, Chantal Combredet
  • Method for quantifying immune cells in tumoral tissues and its applications
    Patent number: 10317408
    Abstract: A method for assessment of a number or density of immune cells in tumoral tissues comprising the steps consisting in: a. providing one or more immunostained slices of tissue section obtained by an automated slide-staining system by using antibodies binding specifically to antigens (markers) expressed by immune cells. b. proceeding to digitalization of the slides of step a. by high resolution scan capture, whereby a high definition (4.6 ?m/pixel or better) digital picture of the slide to be analyzed is obtained, c. detecting the slice of tissue section on the digital picture d. analyzing the slice of tissue section for defining (i) the tumor (CT) and (ii) the invasive margin of the tumor (IM), e. providing a size reference grid with uniformly distributed units having a same surface, said grid being adapted to the size of the tumor to be analyzed, e1. checking the quality of immunostaining, f.
    Type: Grant
    Filed: June 14, 2013
    Date of Patent: June 11, 2019
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Universite Paris Descartes, Assistance Publique-Hopitaux de Paris
    Inventors: Jerome Galon, Franck Pages, Bernhard Mlecnik
  • Method of characterizing molecular diffusion within a body from a set of diffusion-weighted magnetic resonance signals and apparatus for carrying out such a method
    Patent number: 10310044
    Abstract: A computer-implemented method of characterizing molecular diffusion within a body from a set of diffusion-weighted magnetic resonance signals by computing a weighted average of a plurality of multi-compartment diffusion models comprises a same number of compartments, fitted to a set of diffusion-weighted magnetic resonance signals, the weighted average being computed using weights representative of a performance criterion of each of the models; wherein each of the multi-compartment diffusion models comprises a different number of subsets of compartments, the compartments of a same subset being identical to each other.
    Type: Grant
    Filed: April 16, 2015
    Date of Patent: June 4, 2019
    Assignees: UNIVERSITE DE RENNES 1, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE RECHERCHE EN INFORMATIQUE ET EN AUTOMATIQUE (INRIA), INSTITUT NATIONAL DE LA SANTE DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Patrick Perez, Olivier Commowick, Christian Barillot, Aymeric Stamm
  • System for respiratory disorder therapy with stabilization control of stimulation
    Patent number: 10299984
    Abstract: A system includes a processor configured to generate stimulation control signals in response to a detection of a respiratory disorder. The system further includes at least one kinesthetic effector with a vibrating electromechanical transducer applied to a site on a patient's skin for delivering a kinesthetic stimulation energy determined by the control signals. The processor is further configured to determine the effectiveness of a stimulation by detecting a cessation of the respiratory disorder. The processor is further configured to extend the stimulation control signals for a determined duration following the cessation of the respiratory disorder.
    Type: Grant
    Filed: December 7, 2015
    Date of Patent: May 28, 2019
    Assignees: SORIN CRM SAS, INSERM-INSTITUT DE LA RECHERCHE MÉDICALE, UNIVERSITÉ JOSEPH FOURIER, UNIVERSITÉ DE RENNES 1
    Inventors: Amel Amblard, Laurence Graindorge, Delphine Feuerstein, Alfredo Hernandez, Jean-Louis Pépin
  • Use of low dose IL-2 for treating autoimmune related or inflammatory disorders
    Patent number: 10293028
    Abstract: The present invention relates to novel therapies for treating autoimmune and inflammatory diseases. More specifically, the present invention relates to a use of low dose interleukin-2 for the treatment of type I diabetes and other autoimmune and/or inflammatory diseases.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: May 21, 2019
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Assistance Publique—Hopitaux De Paris, SORBONNE UNIVERSITE
    Inventors: David Klatzmann, David Saadoun, Patrice Cacoub, Michéle Rosenzwajg, Eliane Piaggio, Gilbert Bensimon, Claude Bernard
  • Soluble fibroblast growth factor receptor 3 (SFGFR3) polypeptides and uses thereof
    Patent number: 10294289
    Abstract: The invention features soluble fibroblast growth factor receptor 3 (sFGFR3) polypeptides. The invention also features methods of using sFGFR3 polypeptides to treat skeletal growth retardation disorders, such as achondroplasia.
    Type: Grant
    Filed: April 2, 2018
    Date of Patent: May 21, 2019
    Assignees: Therachon SAS, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE NICE SOPHIA ANTIPOLIS
    Inventors: Elvire Gouze, Stéphanie Garcia